{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:03:49Z","timestamp":1768863829863,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00292-025-01507-w","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T08:27:43Z","timestamp":1764145663000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["POLQ and DNA-PK inhibition in muscle-invasive bladder cancer","POLQ- und DNA-PK-Inhibition beim muskelinvasiven Harnblasenkarzinom"],"prefix":"10.1007","volume":"47","author":[{"given":"Julia","family":"Pannhausen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Chughtai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kleger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Saar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Eble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny D.","family":"Jonigk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine T.","family":"Gaisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1507_CR1","doi-asserted-by":"crossref","unstructured":"Barletta F, Tappero S, Panunzio A et al (2022) Differences in cancer-specific mortality after trimodal therapy for T2N0M0 bladder cancer according to histological subtype. Cancers 14(23):5766","DOI":"10.3390\/cancers14235766"},{"issue":"6","key":"1507_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford\u00a0AN, Jackson\u00a0SP (2017) ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell 66(6):801\u2013817","journal-title":"Mol Cell"},{"issue":"7538","key":"1507_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature14184","volume":"518","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi\u00a0R, Liu\u00a0JC, Amunugama\u00a0R et\u00a0al (2015) Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair. Nature 518(7538):258\u2013262","journal-title":"Nature"},{"issue":"2","key":"1507_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","volume":"22","author":"A Choudhury","year":"2021","unstructured":"Choudhury\u00a0A, Porta\u00a0N, Hall\u00a0E et\u00a0al (2021) Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol 22(2):246\u2013255","journal-title":"Lancet Oncol"},{"key":"1507_CR5","doi-asserted-by":"crossref","unstructured":"Chughtai AA, Pannhausen J, Dinger P et al (2022) Effective radiosensitization of bladder cancer cells by pharmacological inhibition of DNA-PK and ATR. Biomedicines 10(6):1277","DOI":"10.3390\/biomedicines10061277"},{"key":"1507_CR6","doi-asserted-by":"crossref","unstructured":"Deng S, Vlatkovic T, Li M et al (2022) Targeting the DNA damage response and DNA repair pathways to enhance radiosensitivity in colorectal cancer. Cancers 14(19):4874","DOI":"10.3390\/cancers14194874"},{"issue":"6","key":"1507_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s10147-019-01409-x","volume":"24","author":"A Dotson","year":"2019","unstructured":"Dotson\u00a0A, May\u00a0A, Davaro\u00a0F et\u00a0al (2019) Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy. Int J Clin Oncol 24(6):706\u2013711","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1507_CR8","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","volume":"10","author":"JHL Fok","year":"2019","unstructured":"Fok\u00a0JHL, Ramos-Montoya\u00a0A, Vazquez-Chantada\u00a0M et\u00a0al (2019) AZD7648 is a\u00a0potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun 10(1):5065","journal-title":"Nat Commun"},{"issue":"2","key":"1507_CR9","first-page":"141","volume":"75","author":"CC Hage","year":"2025","unstructured":"Hage\u00a0CC, Gebrael\u00a0G, Sayegh\u00a0N et\u00a0al (2025) A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin 75(2):141\u2013167","journal-title":"CA Cancer J Clin"},{"issue":"2\u20133","key":"1507_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pbiomolbio.2014.12.003","volume":"117","author":"N Jette","year":"2015","unstructured":"Jette\u00a0N, Lees-Miller\u00a0SP (2015) The DNA-dependent protein kinase: a\u00a0multifunctional protein kinase with roles in DNA double strand break repair and mitosis. Prog Biophys Mol Biol 117(2\u20133):194\u2013205","journal-title":"Prog Biophys Mol Biol"},{"issue":"1","key":"1507_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00345-024-05196-7","volume":"42","author":"E Kaufmann","year":"2024","unstructured":"Kaufmann\u00a0E, Aeppli\u00a0S, Arnold\u00a0W et\u00a0al (2024) Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a\u00a0systematic review. World J Urol 42(1):527","journal-title":"World J Urol"},{"issue":"11","key":"1507_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/14737140.2023.2257389","volume":"23","author":"F Koga","year":"2023","unstructured":"Koga\u00a0F (2023) Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future. Expert Rev Anticancer Ther 23(11):1127\u20131139","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"1507_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1078-0432.CCR-23-1531","volume":"30","author":"A Laroche-Clary","year":"2024","unstructured":"Laroche-Clary\u00a0A, Josensi\u00a0C, Derieppe\u00a0M\u2011A et\u00a0al (2024) Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas. Clin Cancer Res 30(3):629\u2013637","journal-title":"Clin Cancer Res"},{"issue":"7538","key":"1507_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nature14157","volume":"518","author":"PA Mateos-Gomez","year":"2015","unstructured":"Mateos-Gomez\u00a0PA, Gong\u00a0F, Nair\u00a0N et\u00a0al (2015) Mammalian polymerase \u03b8 promotes alternative NHEJ and suppresses recombination. Nature 518(7538):254\u2013257","journal-title":"Nature"},{"issue":"1","key":"1507_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40164-024-00579-3","volume":"13","author":"MK Melzer","year":"2024","unstructured":"Melzer\u00a0MK, Ma\u00a0Y, Lindenmayer\u00a0J et\u00a0al (2024) Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction\u2014feasibility and real world experience. Exp Hematol Oncol 13(1):112","journal-title":"Exp Hematol Oncol"},{"issue":"21","key":"1507_CR16","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1158\/0008-5472.CAN-17-1754","volume":"77","author":"E Metzger","year":"2017","unstructured":"Metzger\u00a0E, Stepputtis\u00a0SS, Strietz\u00a0J et\u00a0al (2017) KDM4 inhibition targets breast cancer stem-like cells. Cancer Res 77(21):5900\u20135912","journal-title":"Cancer Res"},{"issue":"6","key":"1507_CR17","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1016\/j.clgc.2017.07.008","volume":"15","author":"A Minato","year":"2017","unstructured":"Minato\u00a0A, Fujimoto\u00a0N, Kubo\u00a0T (2017) Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder. Clin Genitourin Cancer 15(6):e1063\u2013e1067","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"1507_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","volume":"83","author":"J Murai","year":"2023","unstructured":"Murai\u00a0J, Pommier\u00a0Y (2023) BRCAness, homologous recombination deficiencies, and synthetic lethality. Cancer Res 83(8):1173\u20131174","journal-title":"Cancer Res"},{"key":"1507_CR19","first-page":"100698","volume":"44","author":"A Navran","year":"2024","unstructured":"Navran\u00a0A, Al-Mamgani\u00a0A, Elzinga\u00a0H et\u00a0al (2024) Phase\u00a0I feasibility study of olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma. Clin Transl Radiat Oncol 44:100698","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"1507_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto\u00a0GJ, Amin\u00a0MB, Berney\u00a0DM et\u00a0al (2022) The 2022 world health organization classification of tumors of the urinary system and male genital organs-part\u00a0B: prostate and urinary tract tumors. Eur Urol 82(5):469\u2013482","journal-title":"Eur Urol"},{"issue":"8","key":"1507_CR21","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1078-0432.CCR-22-2977","volume":"29","author":"G Rodriguez-Berriguete","year":"2023","unstructured":"Rodriguez-Berriguete\u00a0G, Ranzani\u00a0M, Prevo\u00a0R et\u00a0al (2023) Small-molecule Pol\u03b8 inhibitors provide safe and effective tumor radiosensitization in preclinical models. Clin Cancer Res 29(8):1631\u20131642","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1507_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/1078-0432.CCR-23-1129","volume":"30","author":"PB Romesser","year":"2024","unstructured":"Romesser\u00a0PB, Capdevila\u00a0J, Garcia-Carbonero\u00a0R et\u00a0al (2024) A phase\u00a0Ib study of the DNA-PK inhibitor peposertib combined with neoadjuvant chemoradiation in patients with locally advanced rectal cancer. Clin Cancer Res 30(4):695\u2013702","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1507_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","volume":"118","author":"M Samuels","year":"2024","unstructured":"Samuels\u00a0M, Falkenius\u00a0J, Bar-Ad\u00a0V et\u00a0al (2024) A phase\u00a01\u00a0study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors. Int J Radiat Oncol Biol Phys 118(3):743\u2013756","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1507_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trecan.2020.09.007","volume":"7","author":"A Schrempf","year":"2021","unstructured":"Schrempf\u00a0A, Slyskova\u00a0J, Loizou\u00a0JI (2021) Targeting the DNA repair enzyme polymerase \u03b8 in cancer therapy. Trends Cancer 7(2):98\u2013111","journal-title":"Trends Cancer"},{"issue":"3","key":"1507_CR25","first-page":"199","volume":"10","author":"P Singh","year":"2024","unstructured":"Singh\u00a0P, Ballas\u00a0L, Sonpavde\u00a0GP et\u00a0al (2024) Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer. BLC 10(3):199\u2013213","journal-title":"BLC"},{"issue":"7","key":"1507_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.eursup.2008.04.006","volume":"7","author":"G Urdaneta","year":"2008","unstructured":"Urdaneta\u00a0G, Solsona\u00a0E, Palou\u00a0J (2008) Intravesical chemotherapy and BCG for the treatment of bladder cancer: evidence and opinion. Eur Urol Suppl 7(7):542\u2013547","journal-title":"Eur Urol Suppl"},{"issue":"1","key":"1507_CR27","doi-asserted-by":"publisher","first-page":"19999","DOI":"10.1038\/s41598-024-70858-w","volume":"14","author":"ZJ Waldrip","year":"2024","unstructured":"Waldrip\u00a0ZJ, Acharya\u00a0B, Armstrong\u00a0D et\u00a0al (2024) Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441. Sci Rep 14(1):19999","journal-title":"Sci Rep"},{"key":"1507_CR28","doi-asserted-by":"publisher","first-page":"103689","DOI":"10.1016\/j.dnarep.2024.103689","volume":"139","author":"T Wang","year":"2024","unstructured":"Wang\u00a0T, Kyle\u00a0AH, Baker\u00a0JHE et\u00a0al (2024) DNA-PK inhibitor AZD7648 is a\u00a0more portent radiosensitizer than PARP inhibitor olaparib in BRCA\u00a01\/2 deficient tumors. DNA Repair 139:103689","journal-title":"DNA Repair"},{"issue":"1","key":"1507_CR29","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","volume":"12","author":"D Zatreanu","year":"2021","unstructured":"Zatreanu\u00a0D, Robinson\u00a0HMR, Alkhatib\u00a0O et\u00a0al (2021) Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun 12(1):3636","journal-title":"Nat Commun"},{"issue":"5","key":"1507_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","volume":"19","author":"FT Zenke","year":"2020","unstructured":"Zenke\u00a0FT, Zimmermann\u00a0A, Sirrenberg\u00a0C et\u00a0al (2020) Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models. Mol Cancer Ther 19(5):1091\u20131101","journal-title":"Mol Cancer Ther"}],"container-title":["Die Pathologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01507-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-025-01507-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01507-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:57:24Z","timestamp":1768816644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-025-01507-w"}},"subtitle":["Enhancing radiosensitivity with novel DNA damage response inhibitors to improve radiotherapy outcomes","Steigerung der Radiosensitivit\u00e4t durch neuartige DNA-Damage-Response-Inhibitoren zur Verbesserung der Strahlentherapie"],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":30,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1007\/s00292-025-01507-w","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.\u00a0Pannhausen, A.A.\u00a0Chughtai, M.K.\u00a0Melzer, Y.\u00a0Ma, J.\u00a0Wirtz, A.\u00a0Kleger, M.\u00a0Saar, M.J.\u00a0Eble, D.D.\u00a0Jonigk, M.\u00a0Rose, and N.T.\u00a0Gaisa declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients gave written informed consent, and experiments followed the regulations of the RWTH centralized biomaterial bank and the Declaration of Helsinki. This study was approved by the Institutional Ethical Review Board of the Medical Faculty of RWTH Aachen University (EK 268\/21, EK 206\/09\u00a0study number 199 and 311).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}